Ncardia

Ncardia’s mission is to bring better medicines to patients faster using our stem cell technology platform. Our cell model portfolio includes hiPSC-derived cardiovascular, neural and immune cells.

For gene therapy companies we have extensive experience from creation of predictive in vitro disease models, to assay development and phenotypic screening for use in evaluating a gene therapy’s ability to rescue a defective phenotype and restore normal functionality.

For cell therapy developers, we partner to innovate iPSC-derived advanced therapies and develop processes to manufacture cell therapy products at scale whilst minimizing CoGs.